{"classes":[{"categories":[{"measurements":[{"comment":"Limited number had events.","groupId":"OG000","lowerLimit":"65.4","upperLimit":"NA","value":"97.6"},{"comment":"Limited number had events.","groupId":"OG001","lowerLimit":"38.1","upperLimit":"NA","value":"59.1"},{"comment":"Limited number had events.","groupId":"OG002","lowerLimit":"39.9","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"18"}],"units":"Participants"}],"description":"Overall Survival (OS) based on Kaplan-Meier method is defined as the time from registration to death due to any cause, or censored at date last known alive.","dispersionType":"90% Confidence Interval","groups":[{"description":"* Participants will receive eribulin intravenously on Day 1 and Day 8\n* Pembrolizumab is administered intravenously Day 1, on a 21-day cycle\n\nEribulin: The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division. Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die. The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink. They also induce cell suicide (self-death or apoptosis).\n\nPembrolizumab: The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.","id":"OG000","title":"Liposarcomas"},{"description":"* Participants will receive eribulin intravenously on Day 1 and Day 8\n* Pembrolizumab is administered intravenously Day 1, on a 21-day cycle\n\nEribulin: The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division. Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die. The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink. They also induce cell suicide (self-death or apoptosis).\n\nPembrolizumab: The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.","id":"OG001","title":"Leiomyosarcomas"},{"description":"* Participants will receive eribulin intravenously on Day 1 and Day 8\n* Pembrolizumab is administered intravenously Day 1, on a 21-day cycle\n\nEribulin: The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division. Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die. The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink. They also induce cell suicide (self-death or apoptosis).\n\nPembrolizumab: The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.","id":"OG002","title":"Undifferentiated Pleomorphic Sarcomas"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Median Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Weeks"}